Evaluation of regorafenib in colorectal cancer and GIST

The Lancet

Volumn 381, Issue 9863, 2013, Pages 273-275

  Waddell, Tom ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROURACIL; IMATINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; RAF PROTEIN; REGORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANOREXIA; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG MARKETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NOTE; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VOICE CHANGE; WEIGHT REDUCTION;

EID: 84872916615     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62006-6     Document Type: Note

References (15)

1. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-55.
2. Grothey A, Van Cutsem E, Sobrero A, et al, for the CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2012; published online Nov 22. http://dx.doi.org/10.1016/S0140- 6736(12)61900-.X.
3. Demetri GD, Reichardt P, Kang Y-K, et al, on behalf of all GRID study investigators. Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2012; published online Nov 22. http://dx.doi. org/10.1016/S0140-6736(12) 61857-1.
4. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; 106: 1722-27.
5. George S, Wang Q, Heinrich MC, et al. Effi cacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-07.
6. National Cancer Institute. Surveillance Epidemiology and End Results. http://seer.cancer.gov/(accessed Nov 19, 2012).
7. Saltz LB, Cox JV, Blanke C, et al, for the Irinotecan Study Group. Irinotecan plus fl uorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14.
8. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fl uorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as fi rst-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
9. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-47.
10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-37.
11. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-49.
12. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.
13. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743-49.
14. Demetri GD, van Oosterom AT, Garrett CR, et al. Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
15. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-59.